Innerva Pharmaceuticals
- Company typePrivate
- Founded2021
- HeadquartersBarcelona, Spain
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
Innerva Pharmaceuticals firmographics
Firmographics- Name
- Innerva Pharmaceuticals
- Legal name
- INNERVA PHARMACEUTICALS
- Website
- https://innervapharma.com
- Company type
- Private
- Founded year
- 2021
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
Innerva Pharmaceuticals industry classification
Industry- Product category
- Ophthalmic Pharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Ophthalmology Specialty Pharmaceuticals (HLAIACAK)
- akta.pro secondary industries
- Ophthalmology Pharmaceuticals (HLAIAAAL), Ocular Drug Delivery Devices (Eye Droppers/Inserts) (HLAHAIAL)
Keywords
Where Innerva Pharmaceuticals is headquartered
LocationHeadquarters
- HQ city
- Barcelona
- HQ country
- Spain
- HQ region
- Europe
Offices1 record
Markets served
Innerva Pharmaceuticals business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Others
Revenue model
- Pharmaceutical Product Sales: Once approved, Innerva plans to commercialize INE-1001 as a prescription pharmaceutical for Dry Eye Disease and other ocular surface pain conditions. Revenue model will be traditional pharmaceutical product sales through prescription channels.
Go-to-market motion1 record
Marketing channels1 record
Innerva Pharmaceuticals product offering
Product offeringCore offering
Innerva Pharmaceuticals is developing INE-1001, a topical ophthalmic formulation containing a first-in-class PIEZO2 ion channel inhibitor for the treatment of ocular surface pain, with a primary indication in Dry Eye Disease. The product uses pharmacological blockade of mechanosensitive PIEZO2 ion channels in corneal nerve endings to provide a non-narcotic mechanism for treating ocular pain. The drug candidate is in pre-clinical development with first-in-human Phase 1/2a clinical trials planned for 2026.
Product overview
Innerva Pharmaceuticals is a single-product biotech company developing novel therapies for ocular pain. The company is focused exclusively on INE-1001, a first-in-class topical ophthalmic drug candidate that uses pharmacological blockade of PIEZO2 ion channels to treat Dry Eye Disease and other ocular surface pain conditions. The product is currently in preclinical development with Phase 1/2a clinical trials planned for 2026.
Differentiator
Problem solved
Functional benefit
Products and services
- INE-1001 A topical ophthalmic formulation containing a first-in-class PIEZO2 inhibitor with a differentiated, non-narcotic mechanism of action. Being developed for Dry Eye Disease (DED) progressing towards first-in-human Phase 1/2a Proof of Concept study. Targets ocular surface pain via pharmacological blockade of mechanosensitive PIEZO2 ion channels in corneal nerve endings.
Quantifiable outcome
- Reduced corneal sensitivity in healthy mice without desensitizing the ocular surface
- +2 more outcomes
Companies that use Innerva Pharmaceuticals
Customer profileSegments3 records
Ideal customer profiles3 records
Innerva Pharmaceuticals technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Innerva Pharmaceuticals partnerships and signals
Strategic signalScale indicators3 records
Recent moves6 records
Expansion highlights4 records
Innerva Pharmaceuticals competitors and assessment
Company assessmentEmerging players
- HanAll Biopharma: HanAll is a Korean biopharma with a DED pipeline (tanfanercept/HL036) and broader ophthalmology ambitions. Comparable as an emerging player pursuing novel mechanisms in dry eye disease with global development plans.
- Vyluma: Vyluma (a Novaliq spin-off) develops ophthalmology assets including therapies for DED and refractive conditions. Comparable as an emerging ophthalmology-focused player with topical ocular delivery expertise relevant to Innerva's topical formulation approach.
- Stuart Therapeutics: Stuart Therapeutics develops novel collagen mimetic peptides for ocular surface disease and DED. Comparable as an emerging player pursuing a differentiated, locally-acting mechanism in the same ocular surface pain indication.
- Kala Bio: Kala Bio is a clinical-stage ophthalmology company developing novel therapies for rare and serious eye diseases. Comparable as an emerging player focused exclusively on ophthalmology with differentiated, often locally-acting therapeutics.
Direct peers
- Novaliq: Novaliq develops water-free topical ophthalmic therapies for DED (CyclASol, NOV03) using a novel vehicle technology. Comparable as a direct peer in DED with a differentiated formulation/delivery approach targeting ocular surface disease.
- Aldeyra Therapeutics: Aldeyra is a clinical-stage biotech developing novel small-molecule approaches for dry eye disease (reproxalap) and other immune-mediated diseases. Highly comparable as a direct peer pursuing a differentiated mechanism in the same DED indication with similar development stage.
- Oyster Point Pharma: Oyster Point developed Tyrvaya (varenicline nasal spray) for DED and was acquired by Viatris. Directly comparable as a focused DED therapeutics company with a novel mechanism of action that expanded treatment options in the same market Innerva targets.
- Mitotech SA: Mitotech developed SkQ1 (plastoquinone-decyl-triphenylphosphonium) for DED and ran multiple Phase 3 trials. Comparable as a direct peer in DED with a novel mechanism pursuing the same ocular surface disease indication.
Broad incumbents
- Bausch + Lomb: Bausch + Lomb is a global ophthalmology incumbent with a broad DED portfolio (artificial tears, pharmaceutical products including Miebo/Perfluorohexyloctane). Comparable as a broad incumbent whose DED franchise overlaps the addressable market Innerva targets.
- Aerie Pharmaceuticals: Aerie Pharmaceuticals acquired Innerva's predecessor company Avizorex Pharma in 2019 (AR-15512/AVX-012, now in Phase 3 for DED) and is developing multiple ophthalmology assets. Directly comparable as a broad incumbent in ophthalmology with deep DED expertise and the same founder lineage.
Market position
Weaknesses5 records
Competitive moat3 records
Key risks6 records
Key highlights7 records
Customer concentration
Innerva Pharmaceuticals social profiles
Digital presenceInnerva Pharmaceuticals financial estimates
Financial estimateRevenue estimate
Valuation estimate
Innerva Pharmaceuticals leadership team
Management profileNumber of profiles
Profiles6 records
Innerva Pharmaceuticals funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Innerva Pharmaceuticals M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Innerva Pharmaceuticals
What does Innerva Pharmaceuticals do?
Innerva Pharmaceuticals is developing INE-1001, a topical ophthalmic formulation containing a first-in-class PIEZO2 ion channel inhibitor for the treatment of ocular surface pain, with a primary indication in Dry Eye Disease. The product uses pharmacological blockade of mechanosensitive PIEZO2 ion channels in corneal nerve endings to provide a non-narcotic mechanism for treating ocular pain. The drug candidate is in pre-clinical development with first-in-human Phase 1/2a clinical trials planned for 2026.
Is Innerva Pharmaceuticals a public or private company?
Innerva Pharmaceuticals is a private company. It is classified as venture growth investor backed and is currently operating.
When was Innerva Pharmaceuticals founded?
Innerva Pharmaceuticals was founded in 2021. It employs 1 to 10 people.
Where is Innerva Pharmaceuticals based?
Innerva Pharmaceuticals is headquartered in Barcelona, Spain, in the Europe region.
How does Innerva Pharmaceuticals make money?
One revenue line is on record: pharmaceutical Product Sales.
Who are Innerva Pharmaceuticals's main competitors?
Emerging players on record are HanAll Biopharma, Vyluma, Stuart Therapeutics and Kala Bio. Direct peers are Novaliq, Aldeyra Therapeutics, Oyster Point Pharma and Mitotech SA. Broad incumbents are Bausch + Lomb and Aerie Pharmaceuticals.
Does Innerva Pharmaceuticals have an API?
No public API is recorded for Innerva Pharmaceuticals.
What industry is Innerva Pharmaceuticals in?
Innerva Pharmaceuticals's product category is Ophthalmic Pharmaceuticals. Its primary akta.pro industry code is HLAIACAK, Ophthalmology Specialty Pharmaceuticals, with a secondary code of HLAIAAAL, Ophthalmology Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.